Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.

ABSTRACT: BACKGROUND:Sixty percent of patients with stage IV melanoma may develop brain metastases, which result in significantly increased morbidity and a poor overall prognosis. Phase 3 studies of melanoma usually exclude patients with untreated brain metastases; therefore, clinical data for intracranial responses to treatments are limited. METHODS:A multicenter, retrospective case series investigation of consecutive BRAF-mutant patients with melanoma brain metastases (MBMs) treated with a combination of BRAF inhibitor encorafenib and MEK inhibitor binimetinib was conducted to evaluate the antitumor response. Assessments included the intracranial, extracranial, and global objective response rates (according to the modified Response Evaluation Criteria in Solid Tumors, version 1.1); the clinical be

SUBMITTER: Holbrook K 

PROVIDER: S-EPMC7004095 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature